News
Another Option for Rare Benign Soft-Tissue Tumor Wins FDA Approval
The Brief
- The FDA approved the small-molecule inhibitor pimicotinib, sold as Pimjetmi, for selected patients with symptomatic tenosynovial giant cell tumour (TGCT).
- The approval covers patients with TGCT who are at high surgical risk.
- Pimicotinib is an oral selective inhibitor of a colony stimulating factor pathway, according to MedPage Today.
Why it matters
TGCT is a rare, usually benign soft-tissue tumour, and this approval adds an oral drug option for patients for whom surgery carries high risk.
Who’s affected
- clinicians treating rare soft-tissue tumours
- patients with symptomatic tenosynovial giant cell tumour
- #oncology
- #fda
- #drug-approval
- #rare-disease
- #tgct
(MedPage Today) -- The FDA approved the small-molecule inhibitor pimicotinib (Pimjetmi) for selected patients with symptomatic tenosynovial giant cell tumor (TGCT) and high surgical risk. An oral selective inhibitor of colony stimulating factor...